TickerFacts.

Nexentis Technologies Inc. (NXTS): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$3.82M
Year ended 2025-12-31
2018-12-31: -$509.0K2019-12-31: -$1.27M2021-12-31: -$4.18M2022-12-31: -$5.15M2025-12-31: -$3.82M-$3.82M
2018-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$3.82Mn/a2026-03-31, From 2025-01-01
No annual figure between 2022-12-31 and 2025-12-31.
2022-12-31-$5.15Mn/m2024-04-01, From 2022-01-01
2021-12-31-$4.18Mn/a2023-03-27, From 2021-01-01
No annual figure between 2019-12-31 and 2021-12-31.
2019-12-31-$1.27Mn/m2021-03-29, From 2019-01-01
2018-12-31-$509.0Kn/a2020-03-30, From 2018-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Nexentis Technologies Inc. (NXTS)2025-12-31-$3.82Mn/a
Incannex Healthcare Inc. (IXHL)2025-06-30-$12.52Mn/m
Evofem Biosciences, Inc. (EVFM)2025-12-31-$2.00Mn/m
Emmaus Life Sciences, Inc. (EMMA)2025-12-31-$12.0Kn/m
Phio Pharmaceuticals Corp. (PHIO)2025-12-31-$7.99Mn/m
Lftd Partners Inc. (LIFD)2025-12-31$1.20Mn/m
Genelux Corp (GNLX)2025-12-31-$26.37Mn/m
Moleculin Biotech, Inc. (MBRX)2025-12-31-$22.73Mn/m
Lite Strategy, Inc. (LITS)2025-06-30-$20.84Mn/m

Compare NXTS, IXHL, EVFM, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗